PMID- 24018781
OWN - NLM
STAT- MEDLINE
DCOM- 20141016
LR  - 20211021
IS  - 1573-2576 (Electronic)
IS  - 0360-3997 (Linking)
VI  - 37
IP  - 1
DP  - 2014 Feb
TI  - Different aspects of sartan + calcium antagonist association compared to the 
      single therapy on inflammation and metabolic parameters in hypertensive patients.
PG  - 154-62
LID - 10.1007/s10753-013-9724-x [doi]
AB  - This study aims to evaluate the effects of an angiotensin receptor blocker 
      (ARB)/calcium channel blocker combination on blood pressure control, lipid 
      profile, insulin sensitivity, and inflammation markers. We randomized 276 
      hypertensive patients to olmesartan 20 mg, amlodipine 10 mg, or a single pill 
      containing an olmesartan/amlodipine combination 20/5 mg for 12 months. We 
      evaluated the following: body weight, systolic and diastolic blood pressure, 
      fasting plasma glucose, fasting plasma insulin (FPI), M value, lipid profile, 
      adiponectin (ADN), high sensitivity C-reactive protein (Hs-CRP), monocyte 
      chemoattractant protein-1 (MCP-1), and macrophage migration inhibitory factor-1beta 
      (MIP-1beta). Olmesartan/amlodipine combination better reduced blood pressure, FPI, 
      homeostasis model assessment index, and increased M value and ADN compared to 
      olmesartan and amlodipine monotherapies. Olmesartan/amlodipine significantly 
      decreased Hs-CRP, MCP-1, and MIP-1beta. In this multicenter, randomized, 
      double-blind, clinical study, ARB/calcium antagonist combination resulted to be 
      more effective than single monotherapies in reducing blood pressure, in improving 
      insulin sensitivity, and in reducing inflammation parameters in patients with 
      stage I essential hypertension.
FAU - Derosa, Giuseppe
AU  - Derosa G
AD  - Department of Internal Medicine and Therapeutics, University of Pavia, Fondazione 
      IRCCS Policlinico S. Matteo, P.le C. Golgi 2, 27100, Pavia, Italy, 
      giuseppe.derosa@unipv.it.
FAU - Cicero, Arrigo F G
AU  - Cicero AF
FAU - Carbone, Anna
AU  - Carbone A
FAU - Querci, Fabrizio
AU  - Querci F
FAU - Fogari, Elena
AU  - Fogari E
FAU - D'Angelo, Angela
AU  - D'Angelo A
FAU - Maffioli, Pamela
AU  - Maffioli P
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Retracted Publication
PL  - United States
TA  - Inflammation
JT  - Inflammation
JID - 7600105
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Drug Combinations)
RN  - 0 (Imidazoles)
RN  - 0 (Lipids)
RN  - 0 (Tetrazoles)
RN  - 1J444QC288 (Amlodipine)
RN  - 8W1IQP3U10 (olmesartan)
SB  - IM
RIN - Derosa G, Cicero AF, Carbone A, Querci F, Fogari E, D'Angelo A, Maffioli P. 
      Inflammation. 2016 Feb;39(1):502. PMID: 26238280
MH  - Amlodipine/*therapeutic use
MH  - Angiotensin II Type 1 Receptor Blockers/*therapeutic use
MH  - Antihypertensive Agents/therapeutic use
MH  - Blood Pressure/drug effects
MH  - Body Mass Index
MH  - Calcium Channel Blockers/*therapeutic use
MH  - Drug Combinations
MH  - Female
MH  - Humans
MH  - Hypertension/*drug therapy
MH  - Imidazoles/*therapeutic use
MH  - Inflammation/drug therapy
MH  - Insulin Resistance
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
MH  - Tetrazoles/*therapeutic use
EDAT- 2013/09/11 06:00
MHDA- 2014/10/17 06:00
CRDT- 2013/09/11 06:00
PHST- 2013/09/11 06:00 [entrez]
PHST- 2013/09/11 06:00 [pubmed]
PHST- 2014/10/17 06:00 [medline]
AID - 10.1007/s10753-013-9724-x [doi]
PST - ppublish
SO  - Inflammation. 2014 Feb;37(1):154-62. doi: 10.1007/s10753-013-9724-x.